Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Common Stock Shares Issued

Common Stock Shares Issued at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
446.9M+22.2%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
105.3M
Tenet Healthcare logo
Tenet HealthcareTHC
159.2M+0.5%
CorMedix logo
CorMedixCRMD
78.4M+15.8%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.41B+185%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001933414-26-000084
Line itemMarch 31, 2026December 31, 2025
Total current liabilities14,71815,113
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 82,454,950 and 81,536,557 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively88
Additional paid-in capital1,134,6441,103,854
Accumulated deficit(496,508)(457,169)
Total stockholders’ equity638,144646,693
Total liabilities and stockholders’ equity$652,862$661,806

Item 1. Financial Statements

FAQ

What is Mineralys Therapeutics, Inc.'s common stock shares issued?
Mineralys Therapeutics, Inc. (MLYS) reported common stock shares issued of 82.5M in Q1 2026.
How has Mineralys Therapeutics, Inc.'s common stock shares issued changed year-over-year?
Mineralys Therapeutics, Inc.'s common stock shares issued increased by 27.1% year-over-year, from 64.9M to 82.5M.
What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock shares issued?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s common stock shares issued has grown at a 133.3% compound annual growth rate (CAGR), from 6.4M to 81.5M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Mineralys Therapeutics, Inc.'s common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude